Insulet Stock News

Insulet's (PODD) drug delivery revenues surge led by increased production volumes, driven by higher-than-expected demand from its partner.

Insulet Corporation (NASDAQ:PODD) concluded the trading at $262.37 on Friday, February 25 with a rise of 2.74% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $255.37 and 5Y monthly beta was reading 0.70 with its price kept floating in the range … Insulet Corporation (PODD) Could Be Possessing A Gold Mine Read More »

Insulet's (PODD) fourth-quarter 2021 revenues improved year over year on a strong performance of Omnipod, both in U.S. and international markets.

Insulet Corp''s (NASDAQ: PODD ) Q4 FY21 revenue increased 25% (25.7% in constant currency) to $307.7 million , exceeding the consensus of $301.06 million. The company brought in $275.8 million in revenues for its Omnipod insulin delivery platform for the quarter, representing a 19.3% increase. Insulet posted Q4 EPS of $0.42, a shift from EPS loss of $(0.26) a year … Full story available on Benzinga.com

Insulet's (PODD) fourth-quarter 2021 revenues improved year over year on a strong performance of Omnipod, both in U.S. and international markets.

Insulet (PODD) delivered earnings and revenue surprises of 40% and 2.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Insulet press release (PODD): Q4 GAAP EPS of $0.42 beats by $0.11.Revenue of $307.7M (+25.0% Y/Y) beats by $7.13M.Gross margin of 69.3%, up 380 basis points.Adjusted EBITDA of…

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2021. Full Year Financial Highlights: Full Year 2021 revenue of $1.1 billion, up 21.5%, or 19.7% in constant currency1, compared to $904.4 million in the prior year, at the high-end of the guidance range of 18% to 20% in constan

Insulet Corporation (PODD) CEO Shacey Petrovic on Q4 2021 Results - Earnings Call Transcript

Insulet (PODD) delivered earnings and revenue surprises of 40% and 2.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase 2b/3 Study Kodiak Sciences

WASHINGTON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the global Artificial Pancreas Device System Market finds that, increasing prevalence of diabetes is expediting market growth. The market growth is attributed to increasing population across the globe as well as lack of precise effective substitute. Total global Artificial Pancreas Device System Market is estimated to reach USD 415.8 Million by 2028. The Market stood at a revenue of USD 95.6 Million in 2021, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 13.1%. Furthermore, rising demand for automated systems for glycemic control, as well as increasing funding in Research and Development (R&D) is projected to augment growth of the global Artificial Pancreas Device System Market, states Vantage Market Research, in a report, titled " Artificial Pancreas Device System Market by Device (Threshold Suspended Device System, CTR System, CTT System), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug A

Dublin, Feb. 09, 2022 (GLOBE NEWSWIRE) -- The "Global Connected Medical Devices Growth Opportunities" report has been added to ResearchAndMarkets.com''s offering. This research study highlights the need for connected medical devices in healthcare and reviews their benefits in improving patient outcomes. Connected medical devices are experiencing major interest from the healthcare industry because of their ability to integrate digital technologies, link with smartphones and online platforms, and share data. Advanced and small-sized sensors are set to accelerate the miniaturization of connected medical devices and improve their accuracy. As such, smart and connected medical devices such as inhalers will increase patients'' adoption of home-based disease management regimes in the next 1 to 2 years. The study covers market drivers, challenges, and key trends in connected medical devices along with the stages of the device life cycle and key data acquisition models. Discussion includes a look at emerging applications for connected medical devices, such as sleep monitoring, clinical trials, and drug delivery.